Michael Cruse Biography and Net Worth

Currently, Michael Cruse holds the position of Senior Vice President-Operations at Reneo Pharmaceuticals, Inc.

He previously was Manager-Information Technology at Noesis Consulting Group, Inc., Manager-Promotional Product at Vision Technologies LLC, Vice President-Corporate Operations at Eledon Pharmaceuticals, Inc. and Vice President-Corporate Operations at Otic Pharma Ltd. (a subsidiary of Eledon Pharmaceuticals, Inc.), Executive Director-Sales Operations at Avanir Pharmaceuticals, Inc. and Manager-Information Technology at Spy Optic, Inc.

Mr. Cruse received an undergraduate degree from Franklin University.

What is Michael Cruse's net worth?: The estimated net worth of Michael Cruse is at least $11,278.54 as of August 31st, 2022. Mr. Cruse owns 6,197 shares of Reneo Pharmaceuticals stock worth more than $11,279 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Cruse may own. Additionally, Mr. Cruse receives an annual salary of $535,470.00 as VP at Reneo Pharmaceuticals. Learn More about Michael Cruse's net worth.
How old is Michael Cruse?: Mr. Cruse is currently 52 years old. There are 3 older executives and no younger executives at Reneo Pharmaceuticals. The oldest executive at Reneo Pharmaceuticals is Mr. Michael G. Grey, Founder & Executive Chairman, who is 71 years old. Learn More on Michael Cruse's age.
What is Michael Cruse's salary?: As the VP of Reneo Pharmaceuticals, Inc., Mr. Cruse earns $535,470.00 per year. The highest earning executive at Reneo Pharmaceuticals is Mr. Gregory J. Flesher, President, CEO & Director, who commands a salary of $569,700.00 per year. Learn More on Michael Cruse's salary.
How do I contact Michael Cruse?: The corporate mailing address for Mr. Cruse and other Reneo Pharmaceuticals executives is , , . Reneo Pharmaceuticals can also be reached via phone at 858-283-0280 and via email at [email protected]. Learn More on Michael Cruse's contact information.
Has Michael Cruse been buying or selling shares of Reneo Pharmaceuticals?: Michael Cruse has not been actively trading shares of Reneo Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, August 31st, Michael Cruse bought 3,212 shares of Reneo Pharmaceuticals stock. The stock was acquired at an average cost of $3.21 per share, with a total value of $10,310.52. Following the completion of the transaction, the chief operating officer now directly owns 6,197 shares of the company's stock, valued at $19,892.37. Learn More on Michael Cruse's trading history.
Who are Reneo Pharmaceuticals' active insiders?: Reneo Pharmaceuticals' insider roster includes Michael Cruse (VP), Gregory Flesher (CEO), Vineet Jindal (CFO), and Bali Muralidhar (Director). Learn More on Reneo Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reneo Pharmaceuticals?: In the last twelve months, Reneo Pharmaceuticals insiders bought shares 4 times. They purchased a total of 670,520 shares worth more than $993,097.95. The most recent insider tranaction occured on September, 24th when Major Shareholder Braden Michael Leonard bought 29,600 shares worth more than $41,736.00. Insiders at Reneo Pharmaceuticals own 17.9% of the company. Learn More about insider trades at Reneo Pharmaceuticals.
Information on this page was last updated on 9/24/2024.

Michael Cruse Insider Trading History at Reneo Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/31/2022	Buy	3,212	$3.21	$10,310.52	6,197
8/29/2022	Buy	83	$3.24	$268.92	30,783
8/25/2021	Buy	2,500	$7.45	$18,625.00	2,500

Michael Cruse Buying and Selling Activity at Reneo Pharmaceuticals

Reneo Pharmaceuticals Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Today's Range

Now: $1.82

$1.68

$1.90

50 Day Range

MA: $1.64

$1.31

$1.82

2 Week Range

Now: $1.82

$0.98

$9.21

Volume

437,500 shs

Average Volume

250,384 shs

Market Capitalization

$60.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Michael Cruse Biography and Net Worth

What is Michael Cruse's net worth?

How old is Michael Cruse?

What is Michael Cruse's salary?

How do I contact Michael Cruse?

Has Michael Cruse been buying or selling shares of Reneo Pharmaceuticals?

Who are Reneo Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Reneo Pharmaceuticals?